Barbituric Acid Or Derivative (including Thioanalogs) Patents (Class 514/270)
-
Publication number: 20120046309Abstract: The present invention relates to the identification of inventive pyrimidine-2,4,6-triones (PYT compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the inventive PYT compounds.Type: ApplicationFiled: May 5, 2010Publication date: February 23, 2012Applicants: NORTHWESTERN UNIVERSITY, CAMBRIA PHARMACEUTICALS, INC.Inventors: Donald R. Kirsch, Radhia Benmohamed, Anthony C. Arvanites, Richard I. Morimoto, Richard B. Silverman, Guoyao Xia
-
Publication number: 20120046307Abstract: The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.Type: ApplicationFiled: October 16, 2009Publication date: February 23, 2012Applicant: UNIVERSITAET DES SAARLANDESInventors: Matthias Engel, Wolfgang Fröhner, Adriane Stroba, Ricardo M. Biondi
-
Publication number: 20120024743Abstract: The present invention relates to semisolid transdermal pharmaceutical preparation having enhanced stability and bioavailability, wherein the particles are coated by a volatile silicon oil component and the thus obtained suspension is dispersed in a gel or cream base.Type: ApplicationFiled: February 5, 2010Publication date: February 2, 2012Applicant: EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAGInventors: Endre Mikulasik, Patrik Fazekas
-
Publication number: 20120028997Abstract: The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.Type: ApplicationFiled: December 16, 2010Publication date: February 2, 2012Inventors: Steven J. Coats, Alexey B. Dyatkin, Wei He, Joseph Lisko, Tamara Miskowski, Janet L. Ralbovsky, Mark Schulz
-
Patent number: 8093386Abstract: There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors of zinc metalloproteinases.Type: GrantFiled: July 25, 2007Date of Patent: January 10, 2012Assignee: Bracco Imaging S.p.AInventors: Armando Rossello, Elisabetta Orlandini, Aldo Balsamo, Laura Panelli, Elisa Nuti
-
Publication number: 20120003335Abstract: The invention provides a method of controlling obesity or type two diabetes in a human. In accordance with the inventive method, the constitutive androstane receptor (CAR) is agonized within the human, which effectively controls obesity or type two diabetes.Type: ApplicationFiled: November 18, 2009Publication date: January 5, 2012Applicant: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Wen Xie, Jie Gao
-
Publication number: 20110319400Abstract: Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D, and Q are defined herein.Type: ApplicationFiled: June 27, 2011Publication date: December 29, 2011Inventors: Christopher M. Flores, Paul R. Wade
-
Patent number: 8076346Abstract: The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.Type: GrantFiled: January 19, 2010Date of Patent: December 13, 2011Assignee: Taro Pharamaceutical Industries Ltd.Inventors: Daniella Gutman, Barrie Levitt, Daniel A. Moros, Avraham Yacobi, Howard Rutman
-
Publication number: 20110301133Abstract: The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.Type: ApplicationFiled: December 8, 2009Publication date: December 8, 2011Applicant: VM Pharma LLCInventors: Jay Jie-Qiang Wu, Ling Wang
-
Publication number: 20110274740Abstract: The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active agent from the single dosage form tapers throughout the administration; and (b) removing the single dosage form from the subjects after the release rate of the active agent is at or below a terminal symptom threshold level.Type: ApplicationFiled: May 5, 2011Publication date: November 10, 2011Inventors: Charles E. DiLiberti, Anu Mahashabde
-
Publication number: 20110269723Abstract: The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may be dispersed or dissolved, and therefore allows for easier preparation and formulation of the pharmaceutical composition.Type: ApplicationFiled: July 12, 2011Publication date: November 3, 2011Applicant: Taro Pharmaceuticals U.S.A., Inc.Inventors: Satish ASOTRA, Xiaoli Wang, Zoltan Bodor
-
Patent number: 8044035Abstract: A trioxopyrimidine-cyclodextrin complex formed of a trioxopyrimidine derivative or a salt thereof and a water-soluble cyclodextrin derivative has improved solubility.Type: GrantFiled: May 27, 2009Date of Patent: October 25, 2011Assignee: Universite De LiegeInventors: Pierre Bartsch, Didier Cataldo, Richard Endele, Brigitte Evrard, Jean-Michel Foidart, Hans-Willi Krell, Gerd Zimmermann
-
Publication number: 20110218210Abstract: Provided herein are compounds, compositions and methods for treating disorders mediated by abnormal cellular proliferation and processes for identifying such compounds.Type: ApplicationFiled: November 3, 2008Publication date: September 8, 2011Applicant: Taiga BiotechnologiesInventors: Yosef Refaeli, Brian Curtis Turner
-
Publication number: 20110178045Abstract: The present invention discloses a method to induce fatty liver in an animal. The steps of the method comprise: feeding an animal with a high calorie diet, and injecting a mitochondrial inhibitor into the animal to inhibit the mitochondrial activity of the animal, then resulting in fat accumulation and inflammation in the liver of the animal.Type: ApplicationFiled: July 8, 2010Publication date: July 21, 2011Applicant: TAIPEI MEDICAL UNIVERSITYInventors: Rong-Hong Hsieh, Sheng-Mei Lin
-
Publication number: 20110070192Abstract: Processes for the preparation of racemic and optically active nucleoside analogs of formula (A) are described. These compounds are useful as anti-infective agents, antisense therapeutic agents and hybridization assay probes.Type: ApplicationFiled: November 8, 2004Publication date: March 24, 2011Inventors: Bruno Tse, Borcherng Hong, Wei-Hung Chen, Yea-Fen Jiang, Shuo-Cang Zhang, Subramanian Marappan, Sepehr Sarshar
-
Publication number: 20110034424Abstract: Provided is a method for the long term treatment of a condition or disease which is one of the indications for NSAID use in a human patient, which comprises administering to the patient a pharmaceutically effective amount of a NSAID and at least 36 mcg per day of cobiprostone or its pharmaceutically acceptable salt, ester, ether or amide. By administering cobiprostone or its pharmaceutically acceptable salt, ester, ether or amide in combination with a NSAID, the patient can receive the NSAID for longer time period.Type: ApplicationFiled: June 29, 2010Publication date: February 10, 2011Applicant: SUCAMPO AGInventor: Ryuji Ueno
-
Publication number: 20110021548Abstract: The present invention relates to inhibitors of MALT1 proteolytic and/or autoproteolytic activity. More specifically, it relates to compounds such as, but not limited to peptide derivates such as Z-LSSR-CHO (see SEQ ID NO:1), Z-LSSR-CMK (see SEQ ID NO:1), Z-GASR-CHO (see SEQ ID NO:2), and Z-GASR-CMK (see SEQ ID NO:2), and small compounds such as 5-{[5-(3-chloro-4-methylphenyl)-2-furyl]methylene}-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione and variants thereof, and the use of those compounds for the preparation of a medicament. The invention relates further to a method to screen for inhibitors of the MALT1 proteolytic and/or autoproteolytic activity.Type: ApplicationFiled: November 20, 2008Publication date: January 27, 2011Inventors: Rudi Beyaert, Peter Marynen, Thijs Baens, Karen Heyninck
-
Publication number: 20110020450Abstract: The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are connected along one or more borders. The plurality of patch units are divisible into units along the one or more borders having one or more lines of separation. Each patch unit is surrounded by a border. The therapeutic patch has at least a backing layer and a therapeutic agent comprising layer. The dosage of therapeutic agent delivered to a patient is proportional to the number of patch unit applied per treatment. The system enables systemic administration of a titratable dosage of therapeutic agent, adjustable by the patient under the direction of a physician, through the skin or mucosa. Moreover, the invention relates to a method of making the titratable dosage transdermal delivery system.Type: ApplicationFiled: September 30, 2010Publication date: January 27, 2011Inventor: Curtis Wright, IV
-
Publication number: 20100311772Abstract: The invention is directed to methods and compositions for inhibiting caspase-independent apoptosis. In particular, methods and compositions for inhibiting Omi/HtrA2 activity, as well as method for identifying other inhibitors of Omi/HtrA2. Also disclosed are Omi/HtrA2 specific substrates and methods for identifying other substrates of Omi/HtrA2.Type: ApplicationFiled: March 31, 2010Publication date: December 9, 2010Applicant: UNIVERSITY OF CENTRAL FLORIDAInventor: Antonis Zervos
-
Publication number: 20100311771Abstract: A method of treating movement disorders comprises administering to a human or animal subject in need of treatment a therapeutically effective amount of at least one compound according to the following formula: wherein R3 and R4 are each independently selected from the group consisting of lower alkyl, phenyl and lower alkyl substituted phenyl, and R1 and R2 are each independently either a hydrogen atom or a radical of the formula wherein R5 and R6 are each independently selected from the group consisting of H, lower alkyl, phenyl and lower alkyl substituted phenyl, its pharmaceutically acceptable salts, prodrugs or metabolites thereof.Type: ApplicationFiled: December 15, 2009Publication date: December 9, 2010Applicant: Taro Pharmaceuticals Industries LimitedInventor: Daniel Moros
-
Publication number: 20100303717Abstract: Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.Type: ApplicationFiled: August 11, 2010Publication date: December 2, 2010Inventor: David Anderson
-
Publication number: 20100305121Abstract: The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII).Type: ApplicationFiled: May 12, 2010Publication date: December 2, 2010Applicant: Burham Institute for Medical ResearchInventors: Jeffrey W. Smith, Robyn D. Richardson
-
Publication number: 20100303754Abstract: A process for the preparation of cyclodextrin oligomers or polymers, whereby the cyclodextrin molecules are coupled to one another covalently via a spacer arm, based on a coupling reaction between an alkyne and an azide producing the formation of an aromatic heterocyclic bridge between the coupled units. Also described are the cyclodextrin oligomers or polymers that are obtained and their uses.Type: ApplicationFiled: October 18, 2007Publication date: December 2, 2010Applicant: BIOCYDEXInventors: Frederic Turpin, Carole Brigand, Yves Cenatiempo, EI Mustapha Belgsir
-
Publication number: 20100286177Abstract: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors.Type: ApplicationFiled: August 8, 2008Publication date: November 11, 2010Applicant: CORTEX PHARMACEUTICALS, INC.Inventors: Rudolf Mueller, Leslie Street
-
Publication number: 20100240682Abstract: To provide an excellent agent for prevention or treatment of an inflammatory disease. The agent for prevention or treatment of an inflammatory disease contains a thymidine phosphorylase inhibitor as an active ingredient, wherein when the thymidine phosphorylase inhibitor is 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a salt thereof, the inflammatory disease is an inflammatory disease other than inflammatory bowel disease.Type: ApplicationFiled: October 10, 2008Publication date: September 23, 2010Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Kazuki Sakamoto, Yoshikazu Sugimoto
-
Publication number: 20100222298Abstract: The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may be dispersed or dissolved, and therefore allows for easier preparation and formulation of the pharmaceutical composition.Type: ApplicationFiled: May 13, 2010Publication date: September 2, 2010Applicant: Taro Pharmaceuticals U.S.A., Inc.Inventors: Satish ASOTRA, Xiaoli WANG, Zoltan BODOR
-
Patent number: 7776871Abstract: A method of treating movement disorders comprises administering to a human or animal subject in need of treatment a therapeutically effective amount of at least one compound according to the following formula: wherein R3 and R4 are each independently selected from the group consisting of lower alkyl, phenyl and lower alkyl substituted phenyl, and R1 and R2 are each independently either a hydrogen atom or a radical of the formula wherein R5 and R6 are each independently selected from the group consisting of H, lower alkyl, phenyl and lower alkyl substituted phenyl, its pharmaceutically acceptable salts, prodrugs, and metabolites thereof.Type: GrantFiled: February 16, 2006Date of Patent: August 17, 2010Assignee: Taro Pharmaceutical Industries Ltd.Inventor: Daniel A. Moros
-
Patent number: 7776870Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.Type: GrantFiled: August 22, 2006Date of Patent: August 17, 2010Assignee: Melior Pharmaceuticals I, Inc.Inventors: Andrew Reaume, Michael S. Saporito
-
Publication number: 20100203001Abstract: The present invention relates to an improved method of formation of disulfide bridges in substances bearing SH groups, in particular peptides, for example by formation of intramolecular disulfide bridges, in which a heterocyclic compound having at least one nitrogen atom (e.g. caffeine or a caffeine-like substance) is used for catalysis of the reaction. It was found, surprisingly, that addition of the heterocyclic substance increases both the yield and the purity of the product bearing disulfide bridges.Type: ApplicationFiled: December 21, 2007Publication date: August 12, 2010Applicant: APLAGEN GMBHInventors: Karsten Knorr, Marco Emgenbroich, Carsten Büngener
-
Publication number: 20100197709Abstract: Methods of providing neuroprotection are disclosed comprising administering a non-sedative barbiturate compound in an amount sufficient to achieve neuroprotection in a mammalian subject. Preferred compounds are in the family of diphenylbarbituric acid and analogs. Preferred doses for a neuroprotective effect exceed the dosage of a corresponding sedative barbiturate without sedative side-effects such as anesthesia and death.Type: ApplicationFiled: April 13, 2010Publication date: August 5, 2010Applicant: Taro Pharmaceutical Industries Ltd.Inventors: Daniel A. Moros, Barrie Levitt, Avraham Yacobi
-
Patent number: 7767670Abstract: The invention provides methods and compositions for treating conditions mediated by various kinases wherein substituted 3-carboxamido isoxazoles compounds are employed. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects.Type: GrantFiled: November 15, 2004Date of Patent: August 3, 2010Assignee: Ambit Biosciences CorporationInventors: Shamal A. Mehta, Robert M. Grotzfeld, Zdravko V. Milanov, Andiliy G. Lai, Hitesh K. Patel, David J. Lockhart
-
Publication number: 20100172916Abstract: The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 9, 2009Publication date: July 8, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Craig Hodulik, Soon Woo
-
Patent number: 7745426Abstract: The present invention relates to compounds and compositions useful for reducing the risk of epileptic occurrences and/or for alleviating epileptic phenomena in patients. In accordance with the invention, the compounds and compositions have at least the following two components: a) vitamin B6-based component selected from pyridoxal, pyridoxamine, pyridoxine, their pharmaceutically acceptable functional derivatives and salts; and b) at least one antiepileptic drug (AED) or anticonvulsive, neuro-protective drug or nootrope compound or moiety. The invention further relates to methods for preventing epileptic episodes and for alleviating epileptic episodes, as well as methods for reducing side effects of antiepileptic drugs.Type: GrantFiled: August 12, 2004Date of Patent: June 29, 2010Assignees: D-Pharm Ltd., Advanced Neuroprotective Systems Ltd.Inventors: Svetlana Dolina, Vitaly Shteiman, Marina Vinnikova, Israel Shapiro
-
Publication number: 20100144769Abstract: The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.Type: ApplicationFiled: January 19, 2010Publication date: June 10, 2010Applicant: TARO PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Daniella Gutman, Barrie Levitt, Daniel Moros, Avraham Yacobi, Howard Rutman
-
Patent number: 7723346Abstract: Methods of providing neuroprotection are disclosed comprising administering a non-sedative barbiturate compound in an amount sufficient to achieve neuroprotection in a mammalian subject. Preferred compounds are in the family of diphenylbarbituric acid and analogs. Preferred doses for a neuroprotective effect exceed the dosage of a corresponding sedative barbiturate without sedative side-effects such as anesthesia and death.Type: GrantFiled: February 16, 2006Date of Patent: May 25, 2010Assignee: Taro Pharmaceutical Industries Ltd.Inventors: Daniel A. Moros, Barrie Levitt, Avraham Yacobi
-
Publication number: 20100093611Abstract: Methods of treating, ameliorating, preventing, or reducing the risk of developing an auto-immune disease and/or an inflammatory condition, such as systemic lupus erythematosus, in a patient, such as a human being, using a therapeutically effective amount of an agent(s) that inhibits the activity of one or more of histone deacetylase (HDAC), IKB kinase (IKK-2), nuclear factor kB (NF-kB), ubiquitin/proteasome and Janus kinase (JAK) are disclosed. Compounds useful in such methods are also presented.Type: ApplicationFiled: May 16, 2008Publication date: April 15, 2010Inventors: Stephen K. Horrigan, Qin Zong, Daniel Soppet, Juana Castaneda, Bo Chen, Ricardo Cibotti, Laurent P. Audoly, Anthony Coyle, Peter Kiener
-
Publication number: 20100080847Abstract: This invention relates to a medicinal composition, which rapidly disintegrates when taken in the oral cavity and shows sufficient hardness upon production, distribution and use in usual manner, can be obtained by adding, to a sugar alcohol and/or saccharide, a sugar alcohol and/or saccharide having a lower melting point than the first-mentioned sugar alcohol and/or saccharide and then subjecting the resulting powder to combined processing of compression and heating. This invention can provide medicinal compositions, which rapidly disintegrate when taken in the oral cavity without water and are excellent in handling ease owing to exhibition of sufficient hardness upon their production, transportation and use in usual manner, and can also provide a process for the production of the medicinal compositions, which is simpler and can avoid contact between an active ingredient and water as needed.Type: ApplicationFiled: December 4, 2009Publication date: April 1, 2010Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Hiroaki Nakagami, Yoshio Kuno
-
Publication number: 20100081678Abstract: Indole derivatives that are useful in the treatment of cancer as a chemotherapeutic agent or radiosensitizing agent.Type: ApplicationFiled: September 30, 2009Publication date: April 1, 2010Inventors: Peter A. Crooks, Thirupathi R. Yerramreddy, Narsimha R. Penthala, Michael L. Freeman, Sekhar R. Konjeti
-
Patent number: 7683071Abstract: The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.Type: GrantFiled: August 10, 2005Date of Patent: March 23, 2010Assignee: Taro Pharmaceuticals Industries Ltd.Inventors: Daniella Gutman, Barrie Levitt, Daniel Moros, Avraham Yacobi, Howard Rutman
-
Patent number: 7674831Abstract: The present invention is directed to the use of a compound of Formula I and physiologically acceptable salts thereof wherein G1, G2, G3, R1, R2, R7, R3, R4, and R5 are defined herein. Compounds according to Formula I can be used to enhance a sweet taste produced by a tastant. The invention is also directed to compositions comprising a compound according to the above formula. Other aspects of the invention provide methods, compounds, and compositions for improved food products wherein the food product comprises a compound according to Formula I and a reduced amount of a sweet tastant.Type: GrantFiled: August 22, 2007Date of Patent: March 9, 2010Assignee: Redpoint Bio CorporationInventors: Karnail S. Atwal, Anita B. Atwal, legal representative, Robert W. Bryant, Ivona Bakaj, Roy Kyle Palmer, Rok Cerne
-
Publication number: 20100055116Abstract: The present invention relates to compositions and methods for targeting c-Rel. In particular, the present invention provides compositions and methods for treating cancers, inflammatory diseases, autoimmune diseases, and transplant rejection by inhibiting c-Rel activity and for regulating c-Rel for research and drug screening applications.Type: ApplicationFiled: April 13, 2007Publication date: March 4, 2010Inventors: Hsiou-chi Liou, Wenzhi Tian, Shuhua Cheng, Constance Y. Hsia, Alex Owyang, Jason J. Hsu
-
Publication number: 20100035904Abstract: Disclosed are new phenobarbital salts, methods of preparation, and uses thereof.Type: ApplicationFiled: August 7, 2009Publication date: February 11, 2010Inventors: Tong Sun, Shawn Watson, Rajesh Manchanda
-
Patent number: 7659277Abstract: The application discloses compounds that inhibit ubiquitin ligase activity. The application further discloses antiviral compounds, anticancer compounds, and compounds useful for the treatment of neurological disorders.Type: GrantFiled: January 11, 2006Date of Patent: February 9, 2010Assignee: Proteologies, Ltd.Inventors: Iris Alroy, Shmuel Tuvia, Yuval Reiss, Ofra Levi-Hacham
-
Patent number: 7601723Abstract: The present invention provides compounds and pharmaceutical compositions that are substituted pyridyl-linked-xanthines of formula I which are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.Type: GrantFiled: February 27, 2006Date of Patent: October 13, 2009Assignee: PGx Health, LLCInventors: Guoquan Wang, Jayson M. Rieger, Robert D. Thompson
-
Publication number: 20090239829Abstract: There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors of zinc metalloproteinases.Type: ApplicationFiled: July 25, 2007Publication date: September 24, 2009Applicant: BRACCO IMAGING SPAInventors: Armando Rossello, Elisabetta Orlandini, Aldo Balsamo, Laura Panelli, Elisa Nuti
-
Publication number: 20090170840Abstract: The present invention generally relates to compounds to treat viral infections and methods of their use. In particular, compounds of the present invention inhibit the activity of NS1 protein, thereby mitigating viral infection and, in particular, influenza virus infection. Accordingly, NS1 protein inhibitors and methods of treatment that employ such inhibitors are contemplated by the present invention.Type: ApplicationFiled: December 8, 2008Publication date: July 2, 2009Inventors: Michael Roth, Beatriz Fontoura, Shuguang Wei, Neal Satterly
-
Publication number: 20090137565Abstract: The invention is directed to methods of treating movement disorders by administering an effective amount of the compound of formula (I) to patients in need thereof. More particularly, the invention is directed to a method for treating myoclonus including administering to a patient a compound of formula (I), wherein the myoclonus is not alcohol responsive essential myoclonus with dystonia. In some embodiments, the myoclonus is posthypoxic myoclonus. The invention is also directed to a method for treating dystonia, essential tremor cerebellar tremor, a tic, or chorea, including administering to a patient a compound of formula (I).Type: ApplicationFiled: November 9, 2005Publication date: May 28, 2009Applicant: The Trustees of Columbia University in the City of New YorkInventor: Steven Frucht
-
Patent number: 7534859Abstract: The present invention is directed to the production of PKC isozyme ? (PKC?)-deficient cells and non-human animals. The present invention is further directed to the identification of PKC? as a target for drugs that reduce anxiety. According to the present invention, PKC?-inhibiting compounds act in synergy with drugs acting at the GABAA receptor. The present invention is also directed to the use of modulators of PKC? to modulate alcohol consumption, self-administration of other drugs of abuse, and the effects of alcohol consumption as well as the use of inhibitors of PKC?, either alone or in conjunction with allosteric agonists of GABAA receptors, to treat conditions, such as addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, and epilepsy, that are amenable to treatment by allosteric agonists of GABAA receptors.Type: GrantFiled: August 8, 2006Date of Patent: May 19, 2009Assignee: The Regents of the University of CaliforniaInventors: Robert O Messing, Clyde W Hodge
-
Publication number: 20090110724Abstract: The present invention relates to compositions and methods for treatment of various forms of pain. Specifically, the method involves administering to a patient a composition comprising butalbital, acetaminophen and caffeine in the gelcap dosage form, to treat and/or alleviate the occurrence or negative effects of various forms of headaches.Type: ApplicationFiled: October 31, 2007Publication date: April 30, 2009Inventor: John A. Giordano
-
Patent number: RE41289Abstract: The subject invention concerns novel compounds that are useful as ultrashort acting hypnotic barbiturates. Specifically exemplified are derivatives of barbituric and thiobarbituric acids. They are rapidly metabolized by blood and tissue enzymes to form polar metabolites with no hypnotic activity and which are rapidly eliminated.Type: GrantFiled: December 20, 2007Date of Patent: April 27, 2010Assignee: ARYx Therapeutics, Inc.Inventors: Pascal Druzgala, Peter G. Milner